U.S. Army Medical Research and Development Command

Developing and fielding life-saving drugs, vaccines, and medical devices that protect our Warfighters and enable them to maintain operational effectiveness will increasingly rely on the use of artificial intelligence. Find out how DHA R&D-MRDC researchers are incorporating the latest FDA risk-assessment guidance into their decision-making processes to ensure safety and efficacy: https://lnkd.in/gz_su4SA #DHA | #MRDC | #MilitaryMedicine

DHA R&D-MRDC congratulates Dr. Chandar Thakur, chief of the Medical Devices and Diagnostics Branch at the Office of Regulated Activities, upon being named DHA R&D-MRDC’s 2024 Employee of the Year award! The award recognizes Thakur’s exemplary regulatory support for the command’s advanced development programs for integrating medical R&D into Warfighter requirements. Read the full story here: https://lnkd.in/eRA_7xVR #DHA | #MRDC | #MilitaryMedicine

Crimean-Congo hemorrhagic fever virus (CCHFV) is a priority pathogen transmitted by tick bites, with no vaccines or specific therapeutics approved to date. This recent study in "Science Translational Medicine" involving researchers from USAMRIID, Albert Einstein College of Medicine, UC Berkeley School of Public Health, academia and industry, sheds light on GP38’s role in viral infections and pathogenesis, and how GP38-specific antibodies particularly mediate protection in vivo. Explore the study to see evidence that GP38 is a #CCHFV virulence factor or viral toxin with a direct role in viral #pathogenesis that is independent of its function in viral glycoprotein biogenesis, and the importance of including GP38 in CCHFV vaccine design. https://lnkd.in/eqYARxd7 #biomedicalresearch #weareriid

After a 7.7-magnitude earthquake on March 28, 2025, WRAIR-AFRIMS teams quickly supported emergency efforts at Bangkok’s Phramongkutklao Hospital. The hospital faced power failures and structural issues, leading to an evacuation via an 11-floor fire escape. Read more about their heroic efforts here: https://lnkd.in/eGpUGmeX

MRDC’s Combat Casualty Care Research Program is proud to announce a feature article in TIME Magazine! The excerpt, titled “Precise Surgical Vision,” highlights a Department of Defense CCCRP-funded project for the TIME’s list of “The Best Inventions of 2024.” To read the full article, please visit the link below ⬇ #ScienceForTheWarfighter

The Department of Defense Combat Casualty Care Research Program is sponsoring the Emergency Transfusion in Females with Childbearing Potential: Mitigating the Risks of Hemolytic Disease of the Fetus and Newborn event! Held at the Hyatt Regency Bethesda, the meeting will present evidence-based guidelines for emergency transfusion in females with childbearing potential, focused on methods to mitigate and manage the risks of hemolytic disease of the fetus and newborn (HDFN). The event is open to the public on November 19th and reserved for expert panel voting on November 20th. To read the full press release, please visit: https://lnkd.in/egnuHnXh  #WhiteHouseInitiative #WomensHealthResearch

MRDC's Combat Casualty Care Research Program is proud to announce a significant advancement in support of the Military Health System. Funded by the CCCRP through the MTEC | Medical Technology Enterprise Consortium), the TBI Navigator app will be released on September 27th, 2024. This technology is designed to guide medical teams through the assessment and management of traumatic brain injuries, while generating real-time reports to aid in fast and accurate communication throughout the continuum of care. To read the full TBI Navigator press release, please visit: Moberg Analytics LinkedIn https://lnkd.in/e5caTA8R

Team MRDC, on July 10, 2024, MG Paula C. Lodi assumed command of MRDC. MG Lodi’s experience and leadership are an asset to the organization as we continue to create and develop medical capabilities for our future force. Follow the link to watch her welcome message. #MilitaryMedicine | #DHAProud

Today, WRAIR had the pleasure of welcoming MG Paula C. Lodi, Commanding General of the U.S. Army Medical Research & Development Command, and Ms. Kathleen L. Berst, Acting Assistant Director Support/Component Acquisition Executive for the Defense Health Agency, along with their teams. The group learned about WRAIR's vast infectious disease and brain health research portfolio. The tour also covered some of our unique capabilities like the Pilot Bioproduction Facility, WRAIR's cGMP-compliant pharmaceutical manufacturing facility, and the Multidrug-Resistant Organism Repository and Surveillance Network, which keeps tabs on antibiotic-resistant bacteria for the Army, Navy, and Air Force. The group also visited our Blast Induced Neurotrauma Branch, where we study head injuries and the impact of repeated blast exposure on the brain, and recieved an exclusive look at BH Gear, our new training program that teaches medics basic behavioral health skills for deployment. We’re thrilled to have shared our capabilities and achievements, and we look forward to the great work we will do together.

We're excited to share that MTEC has partnered with the U.S. Army Medical Research and Development Command (USAMRDC) to drive innovation in combat-related traumatic brain injury (TBI) research. Dr. J.B. Phillips of MRDC's Combat Casualty Care Research Program emphasizes the need for early TBI diagnosis at the point of injury, a critical step in improving outcomes for our Warfighters. Through our unique consortium model and Other Transaction Agreements (OTA), MTEC has dedicated $171 million to brain health research, including TBI detection and PTSD management. Our collaboration ensures that cutting-edge, life-saving technologies reach those who need them most. Together, we're making a difference! Read more in the article linked in the comments #BrainHealth #TBIResearch #MilitaryInnovation #Healthcare #MTEC #USAMRDC #MedicalTechnology #InnovationInHealth #TBI #PTSD #OTA